Pfizer Bullish On Danuglipron’s Position In Oral GLP-1 Race

The company believes it still has a good shot at getting an oral GLP-1 to market ahead of many competitors, if not necessarily ahead of Lilly.

Pfizer reported second quarter financial results • Source: Shutterstock

Despite setbacks, Pfizer Inc. believes its oral GLP-1 agonist danuglipron remains in a competitive position versus rivals. Investors are hyper-focused on the development of danuglipron for obesity, even though it remains relatively early days, because of the multibillion-dollar market opportunity and the fast-changing competitive dynamics.

Key Takeaways
  • Pfizer reported solid second quarter sales and earnings growth, given declining sales of the COVID-19 vaccine Comirnaty, offset by legacy Seagen products.

During Pfizer’s second quarter sales and earnings call on 30 July, CEO Albert Bourla said the company hopes to move...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By 

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By 

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By 

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

More from Business

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By 

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.

Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease

 
• By 

Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.